LncRNA DNAJC3-AS1 Regulates Fatty Acid Synthase via the EGFR Pathway to Promote the Progression of Colorectal Cancer

Abstract

Colorectal cancer (CRC) is one of the most common cancers worldwide. Recent studies have shown that long non-coding RNAs (lncRNAs) are involved in tumorigenesis and the development of CRC. By constructing a differential lncRNA expression profile, we screened gene chips and found that DNAJC3-AS1 was highly expressed in CRC tissues and was associated with poor prognosis in patients with CRC. Further, we proved through assays such as wound healing, colony formation, and Cell Counting Kit-8 (CCK8) that interfering with DNAJC3-AS1 could reduce the proliferation, migration, and invasion of CRC cells. Mechanically, we found that DNAJC3-AS1 regulates fatty acid synthase to promote the progression of CRC via the epidermal growth factor receptor/phosphatidylinositol 3-kinase/protein kinase B/nuclear factor κB signaling pathway. Therefore, DNAJC3-AS1 may be a new target for the diagnosis and therapy of CRC.

LncRNA DNAJC3-AS1 Promotes Hepatocellular Carcinoma (HCC) Progression via Sponging Premature miR-27b

“…DNAJC3-AS1 is an oncogenic lncRNA characterized in several types of cancers. [15][16][17] In colorectal cancer, its expression is increased. DNAJC3-AS1 overexpression interacts with epidermal growth factor receptor (EGFR) pathway to regulate fatty acid synthase, thereby promoting cancer progression.…”

“…DNAJC3-AS1 overexpression interacts with epidermal growth factor receptor (EGFR) pathway to regulate fatty acid synthase, thereby promoting cancer progression. 15 DNAJC3-AS1 expression is also increased in renal cell carcinoma, and it sponges miR-27a-3p to upregulate PRDM14, thereby accelerating cancer development. 16 DNAJC3-AS1 interacts with its sense-cognate gene 17 In the present study, we observed the upregulation of DNAJC3-AS1 in HCC and its role in enhancing cell proliferation.…”

“…The major role of long non-coding RNAs (lncRNAs) is to regulate gene expression rather than coding proteins, suggesting that lncRNAs are promising targets for anticancer therapy. 13,14 DNAJC3 antisense RNA 1 (head to head) (DNAJC3-AS1) accelerates the progression of several cancers, [15][16][17] but the participation of this lncRNA in HCC is unclear. We predicted that DNAJC3-AS1 may interact with miR-27b, which is a cancer-related miRNA in cancers.…”

Close interactions between lncRNAs, lipid metabolism and ferroptosis in cancer

“…The malonyl-CoA produced under the action of ACC1 mainly promotes the synthesis of FAs, while the malonyl-CoA produced under the action of ACC2 mainly inhibits the oxidation of FAs [84], keeping the FA content in the body at a high level. To further meet the needs of tumor cells, ACC is highly expressed in NSCLC [85], cervical squamous cell carcinoma [86] and colorectal cancer [87].…”

“…The mechanisms by which lncRNAs regulate ACC in different tumors are also different. LncRNA DNAJC3-AS1 is highly expressed in colorectal cancer and can regulate the expression of ACC and FASN by activating PI3K/AKT, a recognized oncogenic pathway, thereby promoting tumor progression [87]. Recent studies have demonstrated that lncRNA CTD-2245E15.3 is highly expressed in NSCLC, and its inhibition can regulate lipid metabolism-related genes.…”